Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Chosa

    MCap

    SEK57m

    Last close

    SEK0.80

    ▲ 0.20 (33.33%)

    Vection Technologies

    MCap

    AUD47m

    Last close

    AUD0.04

    ▲ 0.00 (12.90%)

    Metro Bank

    MCap

    GBP684m

    Last close

    GBP1.02

    ▲ 7.90 (8.43%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Executive Interview – TruScreen

Executive Interview – TruScreen

TruScreen (TRU) listed on the NZX in November 2014. The company manufactures and distributes a unique testing device that detects cancerous and pre-cancerous cells in the cervix. The developing world, which has the highest incidence and mortality from cervical cancer, is its target market. TRU has secured China Food and Drug Administration (CFDA) approval to market TruScreen in China and has recently received certification in Mexico. TRU has distribution contracts in 11 international markets, including China, Latin America, Central Asia, Russia, the Middle East and Eastern Europe.

In this interview CEO Martin Dillon discusses the rationale behind TruScreen’s market entry into China, the benefits of the company’s testing device and its future growth strategy, including the launch of new products.

< Previous
Next >

You may also be interested in these:

Healthcare

Recce Pharmaceuticals – executive interview

TMT

VEON – executive interview with CFO Joop Brakenhoff

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free